A Phase II Study of Selective AXL Inhibitor Bemcentinib and Pembrolizumab in Patients with NSCLC Refractory to Anti-PD(L)1

Simple item page
dc.contributor.authorKrebs, M.
dc.contributor.authorBrunsvig, P.
dc.contributor.authorHelland, A.
dc.contributor.authorVinolas, N.
dc.contributor.authorAix, S.
dc.contributor.authorCarcereny, E.
dc.contributor.authorDomine Gomez, M.
dc.contributor.authorTrigo Perez, J. M.
dc.contributor.authorArriola, E.
dc.contributor.authorGarcia Campelo, R.
dc.contributor.authorSpicer, J.
dc.contributor.authorThompson, J.
dc.contributor.authorOrtega Granados, A. L.
dc.contributor.authorHolt, R.
dc.contributor.authorSmethurst, D.
dc.contributor.authorLorens, J.
dc.contributor.authorShoaib, M.
dc.contributor.authorSiddiqui, A.
dc.contributor.authorSchoelermann, J.
dc.contributor.authorLorens, K.
dc.contributor.authorSchmidt, E.
dc.contributor.authorChisamore, M. J.
dc.contributor.authorFelip, E.
dc.contributor.authoraffiliation[Krebs, M.] Christie NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
dc.contributor.authoraffiliation[Krebs, M.] Univ Manchester, Manchester, Lancs, England
dc.contributor.authoraffiliation[Brunsvig, P.] Oslo Univ Hosp, Oslo, Norway
dc.contributor.authoraffiliation[Helland, A.] Oslo Univ Hosp, Inst Canc Res, Norwegian Radium Hosp, Oslo, Norway
dc.contributor.authoraffiliation[Vinolas, N.] Hosp Clin Barcelona, Barcelona, Spain
dc.contributor.authoraffiliation[Aix, S.] Hosp 12 Octubre Carretera Andalucia, Madrid, Spain
dc.contributor.authoraffiliation[Carcereny, E.] Catalan Inst Oncol Badalona, Med Oncol, Badalona, Spain
dc.contributor.authoraffiliation[Carcereny, E.] Hosp Badalona Germans Trias & Pujol, Badalona, Spain
dc.contributor.authoraffiliation[Carcereny, E.] B Argo, Badalona, Spain
dc.contributor.authoraffiliation[Domine Gomez, M.] Hosp Univ Fdn Jimenez Diaz, Madrid, Spain
dc.contributor.authoraffiliation[Trigo Perez, J. M.] Hosp Virgen de La Victoria, Malaga, Spain
dc.contributor.authoraffiliation[Arriola, E.] Hosp Mar, Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Garcia Campelo, R.] Univ Hosp A Coruna Xxiac Sergas, Med Oncol Serv, La Coruna, Spain
dc.contributor.authoraffiliation[Spicer, J.] KingS Coll London, Guys Hosp, London, England
dc.contributor.authoraffiliation[Thompson, J.] Med Coll Wisconsin, Affiliated Hosp, Menomonee Falls, WI USA
dc.contributor.authoraffiliation[Ortega Granados, A. L.] Complejo Hosp Jaen, Med Oncol, Jaen, Spain
dc.contributor.authoraffiliation[Holt, R.] Bergenbio Asa, Bergen, Norway
dc.contributor.authoraffiliation[Smethurst, D.] Bergenbio Asa, Bergen, Norway
dc.contributor.authoraffiliation[Lorens, J.] Bergenbio Asa, Bergen, Norway
dc.contributor.authoraffiliation[Shoaib, M.] Bergenbio Asa, Bergen, Norway
dc.contributor.authoraffiliation[Siddiqui, A.] Bergenbio Asa, Bergen, Norway
dc.contributor.authoraffiliation[Schoelermann, J.] Bergenbio Asa, Bergen, Norway
dc.contributor.authoraffiliation[Lorens, K.] Bergenbio Asa, Bergen, Norway
dc.contributor.authoraffiliation[Schmidt, E.] Merck & Co Inc, Kenilworth, NJ USA
dc.contributor.authoraffiliation[Chisamore, M. J.] Merck & Co Inc, Rahway, NJ 07065 USA
dc.contributor.authoraffiliation[Felip, E.] Vall DHebron Univ Hosp, Barcelona, Spain
dc.date.accessioned2025-01-07T14:43:20Z
dc.date.available2025-01-07T14:43:20Z
dc.date.issued2019-10-01
dc.identifier.doi10.1016/j.jtho.2019.08.787
dc.identifier.essn1556-1380
dc.identifier.issn1556-0864
dc.identifier.unpaywallURLhttp://www.jto.org/article/S1556086419314704/pdf
dc.identifier.urihttps://hdl.handle.net/10668/26624
dc.identifier.wosID492162202116
dc.issue.number10
dc.issue.numberS
dc.journal.titleJournal of thoracic oncology
dc.journal.titleabbreviationJ. thorac. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario de Jaén
dc.organizationSAS - Hospital Universitario Virgen de la Victoria
dc.page.numberS388-S388
dc.publisherElsevier science inc
dc.rights.accessRightsopen access
dc.subjectbemcentinib
dc.subjectAXL
dc.subjectPembrolizumab
dc.titleA Phase II Study of Selective AXL Inhibitor Bemcentinib and Pembrolizumab in Patients with NSCLC Refractory to Anti-PD(L)1
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number14
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario de Jaén
SAS - Hospital Universitario Virgen de la Victoria

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía